133 related articles for article (PubMed ID: 27505709)
1. Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody.
Zhuang W; Zhang J; Pei L; Fang S; Liu H; Wang R; Su Y
Mol Immunol; 2016 Sep; 77():141-7. PubMed ID: 27505709
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Baker KP; Edwards BM; Main SH; Choi GH; Wager RE; Halpern WG; Lappin PB; Riccobene T; Abramian D; Sekut L; Sturm B; Poortman C; Minter RR; Dobson CL; Williams E; Carmen S; Smith R; Roschke V; Hilbert DM; Vaughan TJ; Albert VR
Arthritis Rheum; 2003 Nov; 48(11):3253-65. PubMed ID: 14613291
[TBL] [Abstract][Full Text] [Related]
3. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
4. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
Halpern WG; Lappin P; Zanardi T; Cai W; Corcoran M; Zhong J; Baker KP
Toxicol Sci; 2006 Jun; 91(2):586-99. PubMed ID: 16517838
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of a monoclonal antibody against human B lymphocyte stimulator.
Sun J; Li Y; Sun Y; Yu M; Feng J; Shen B
Hybridoma (Larchmt); 2006 Apr; 25(2):80-5. PubMed ID: 16704308
[TBL] [Abstract][Full Text] [Related]
6. Expression and effects of B-lymphocyte stimulator and its receptors in T cell-mediated autoimmune arthritis.
Chang Y; Sun X; Jia X; Xu S; Wei F; Yang X; Wei W
Int Immunopharmacol; 2015 Feb; 24(2):451-457. PubMed ID: 25598291
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
Zhang J; Roschke V; Baker KP; Wang Z; Alarcón GS; Fessler BJ; Bastian H; Kimberly RP; Zhou T
J Immunol; 2001 Jan; 166(1):6-10. PubMed ID: 11123269
[TBL] [Abstract][Full Text] [Related]
8. BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target.
Baker KP
Autoimmun Rev; 2004 Jul; 3(5):368-75. PubMed ID: 15288003
[TBL] [Abstract][Full Text] [Related]
9. Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound.
Nicoletti AM; Kenny CH; Khalil AM; Pan Q; Ralph KL; Ritchie J; Venkataramani S; Presky DH; DeWire SM; Brodeur SR
J Pharmacol Exp Ther; 2016 Oct; 359(1):37-44. PubMed ID: 27440419
[TBL] [Abstract][Full Text] [Related]
10. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases.
Nardelli B; Moore PA; Li Y; Hilbert DM
Leuk Lymphoma; 2002 Jul; 43(7):1367-73. PubMed ID: 12389615
[TBL] [Abstract][Full Text] [Related]
11. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator.
Auyeung-Kim DJ; Devalaraja MN; Migone TS; Cai W; Chellman GJ
Reprod Toxicol; 2009 Dec; 28(4):443-55. PubMed ID: 19631735
[TBL] [Abstract][Full Text] [Related]
12. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA.
Liu MY; Han W; Ding YL; Zhou TH; Tian RY; Yang SL; Liu H; Gong Y
Acta Biochim Biophys Sin (Shanghai); 2005 Jun; 37(6):415-20. PubMed ID: 15944757
[TBL] [Abstract][Full Text] [Related]
14. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
Scholz JL; Oropallo MA; Sindhava V; Goenka R; Cancro MP
Lupus; 2013 Apr; 22(4):350-60. PubMed ID: 23553778
[TBL] [Abstract][Full Text] [Related]
15. Activation and accumulation of B cells in TACI-deficient mice.
Yan M; Wang H; Chan B; Roose-Girma M; Erickson S; Baker T; Tumas D; Grewal IS; Dixit VM
Nat Immunol; 2001 Jul; 2(7):638-43. PubMed ID: 11429549
[TBL] [Abstract][Full Text] [Related]
16. [B lymphocyte stimulator in systemic lupus erythematosus].
Mercado U
Rev Med Inst Mex Seguro Soc; 2012; 50(4):349-50. PubMed ID: 23234733
[TBL] [Abstract][Full Text] [Related]
17. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.
Moore PA; Belvedere O; Orr A; Pieri K; LaFleur DW; Feng P; Soppet D; Charters M; Gentz R; Parmelee D; Li Y; Galperina O; Giri J; Roschke V; Nardelli B; Carrell J; Sosnovtseva S; Greenfield W; Ruben SM; Olsen HS; Fikes J; Hilbert DM
Science; 1999 Jul; 285(5425):260-3. PubMed ID: 10398604
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF).
Sène D; Limal N; Ghillani-Dalbin P; Saadoun D; Piette JC; Cacoub P
Rheumatology (Oxford); 2007 Jan; 46(1):65-9. PubMed ID: 16782735
[TBL] [Abstract][Full Text] [Related]
19. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.
Ding C
Expert Opin Biol Ther; 2008 Nov; 8(11):1805-14. PubMed ID: 18847314
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF.
Abu-Rish EY; Amrani Y; Browning MJ
Rheumatology (Oxford); 2013 Jul; 52(7):1190-201. PubMed ID: 23436580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
